SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 49.95-6.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (18195)10/30/2005 7:05:04 AM
From: Biotech Jim  Read Replies (1) of 52153
 
In my view the DPPIV inhibitors will not have sufficient substrate available to block metabolism in the circulation. The inhibitors will be useful in some but not all patients. An oral agonist with safety and tolerability would be the grand slam home run.

The weight gain effects and the beta cell neogenesis will be key here. Does anyone know if the NVS or MRK inhibitors get into the CNS? There is sufficient reason for blockade in CNS pathways as well as in the periphery, though at least some of the incretin peptide sites of action in the brain are at sites of compromised (ie leaky, no tight capillary junctions) blood brain barrier.

JMHO.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News